Skip to main content

Table 2 OI Group Demographic

From: Orthostatic intolerance in chronic fatigue syndrome

 

No OI Controls

N = 21

Postural OI Controls

N = 4

No OI CFS

N = 11

Persistent OI CFS

N = 16

Postural OI CFS

N = 12

ANOVA

Age

44 ± 18

41 ± 25

44 ± 9

51 ± 15

46 ± 13

ns

Males

13

1

3

5

3

ns

Females

8

3

8

11

9

ns

BMI

28.74 ± 4.56

22.15 ± 1.71

25.8 ± 4.7

25.9 ± 4.6

27.6 ± 7.2

ns

COMPASS-31 [13]

      

COMPASS-31 Sum

12.06 ± 8.60*

29.09 ± 7.96

22.40 ± 15.26

36.45 ± 9.10

27.25 ± 15.37

ns

OI

6.11 ± 7.10*

19.00 ± 11.49

12.40 ± 10.23

17.14 ± 8.22

13.45 ± 8.81

ns

Vasomotor

0*

0

0

0.65 ± 0.93

0.98 ± 0.97

p < 0.001

Secretomotor

1.47 ± 2.03*

2.68 ± 3.21

1.50 ± 2.68

5.66 ± 3.72

2.73 ± 3.72

p < 0.001

GI

3.01 ± 3.52*

5.80 ± 3.30

5.09 ± 3.62

9.37 ± 3.48

6.90 ± 4.89

p < 0.001

Bladder

0.58 ± 1.19

0.28 ± 0.56

0.78 ± 1.18

1.11 ± 1.63

1.21 ± 1.44

ns

Pupillomotor

0.89 ± 0.57*

1.33 ± 0.90

2.63 ± 1.17

2.50 ± 0.61

1.97 ± 0.71

p < 0.001

CFS_Q_Fatigue [20]

0.94 ± 1.11*

2.50 ± 1.29*

3.27 ± 1.19

3.53 ± 0.64

3.42 ± 0.67

p < 0.001

CFS_Q_Sum8 [20]

4.72 ± 5.17*

11.25 ± 2.75*

16.64 ± 6.30

19.60 ± 5.05

17.17 ± 4.45

p < 0.001

Chalder_11 [27]

11.63 ± 4.13*

18.00 ± 7.66*

20.36 ± 7.10

23.73 ± 5.79

24.00 ± 6.34

p < 0.001

SF-36 [28]

      

Physical functioning

88.68 ± 21.72*

87.50 ± 10.41*

52.73 ± 33.57

44.33 ± 24.12

42.50 ± 22.21

p < 0.001

Role—physical

90.79 ± 12.54*

25.00 ± 48.99*

20.45 ± 40.03

6.67 ± 17.59

2.08 ± 7.22

p < 0.001

Role—emotional

92.28 ± 21.02

50.00 ± 57.54

57.58 ± 47.35

68.89 ± 46.23

83.33 ± 38.92

ns

Vitality

75.79 ± 19.51*

36.75 ± 20.55*

40.73 ± 27.46

28.07 ± 23.85

37.00 ± 18.12

p < 0.001

Mental Health

77.26 ± 13.54

57.00 ± 27.59

63.64 ± 10.95

66.93 ± 20.03

72.00 ± 17.14

ns

Social function

88.16 ± 17.42*

46.88 ± 27.72*

43.18 ± 33.24

27.50 ± 21.75

29.17 ± 26.29

p < 0.001

Bodily pain

87.63 ± 15.79*

76.50 ± 37.11*

48.82 ± 30.35

42.40 ± 22.70

50.17 ± 29.29

p < 0.001

General Health

75.79 ± 19.51*

36.75 ± 20.55*

40.73 ± 27.46

28.07 ± 23.85

37.00 ± 18.12

p < 0.001

  1. There were no significant differences in demographics between groups. The 3 CFS groups were significantly different from both SC groups for measures of autonomic dysfunction, cognitive dysfunction, fatigue, pain, and quality of life (p < 0.05, Tukey’s HSD). The CFS Persistent OI group had significantly higher scores on the COMPASS-31 than the CFS No OI group and scored significantly higher on headache, neurological, and ear/sinus-related questions on a systemic complaints questionnaire (p < 0.05, Tukey’s HSD)